Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opthea Limited (AU:OPT)
ASX:OPT
Holding AU:OPT?
Track your performance easily
OPT Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.33 - AU$0.96
Previous CloseAU$0.65
Volume875.27K
Average Volume (3M)5.35M
Market Cap
AU$751.97M
Enterprise ValueAU$530.28M
Total Cash (Recent Filing)$172.47M
Total Debt (Recent Filing)$93.03K
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Feb 26, 2025EPS Estimate
-AU$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding404,975,423
10 Day Avg. Volume2,182,284
30 Day Avg. Volume5,354,520
Standard Deviation0.18
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1222.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.25K
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.30Price Target Upside108.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Opthea Limited News
PremiumCompany Announcements
Opthea Limited Appoints New Director with Stock Options
PremiumCompany Announcements
Opthea Secures A$15.9 Million Boost for R&D Efforts
PremiumCompany Announcements
Opthea Limited Announces Successful AGM Resolutions
PremiumCompany Announcements
Opthea Limited Strengthens Board Amidst Key Data Preparations
PremiumCompany Announcements
Opthea Limited Advances in Wet AMD Treatment
PremiumCompany Announcements
Opthea to Highlight Promising AMD Therapy at Key Events
PremiumCompany Announcements
Opthea Limited to Present at Key November Investor ConferencesOptions Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
2.67% Mutual Funds
― Other Institutional Investors
95.78% Public Companies and
Individual Investors
OPT FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.33 and its highest was AU$0.95 in the past 12 months.
What is Opthea Limited’s market cap?
Currently, no data Available
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Feb 26, 2025 which is in 96 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Aug 30, 2024. The company reported -AU$0.294 earnings per share for the quarter, missing the consensus estimate of -AU$0.155 by -AU$0.139.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Undervalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is -AU$0.22.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,231,094,600 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of -AU$0.294 in its last earnings report, missing expectations of -AU$0.155. Following the earnings report the stock price went up 5.405%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in AU:OPT
---
Opthea Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.30 (108.11% Upside)
AU$1.30 (108.11% Upside)
Blogger Sentiment
Bullish
AU:OPT Sentiment 93%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
91.39%
Trailing 12-Months
Company Description
Opthea Limited
Opthea Ltd. is engaged in the development of biological therapeutics for cancer and other serious diseases. It is a biologics drug developer building on significant intellectual property portfolio around Vascular Endothelial Growth Factor C and D angiogenic molecules and R3. The company focuses on vascular endothelial growth factors to develop truly novel therapies to extend and improve the lives of cancer sufferers. Opthea was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
---
OPT Stock 12 Month Forecast
Average Price Target
AU$1.30
▲(108.11% Upside)
Technical Analysis
ADMA Biologics
―
Brainstorm Cell Therapeutics
―
Cardiff Oncology
―
Durect
―
Opthea Limited
―
Best Analysts Covering OPT
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+96.50%
reiterated a buy rating 2 months ago
Copying Thomas Wakim's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +96.50% per trade.
---